0A5R

Noticias Calliditas Therapeutics Ab

Las mejores ofertas para acceder a los datos en tiempo real!
Real-time Level 1 for London Stock Exchange
Suscripción Mensual
Por sólo
US$29.56
Real-time Level 2 for London Stock Exchange
Suscripción Mensual
Por sólo
US$77.61
Real-time London Stock Exchange & FTSE
Suscripción Mensual
Por sólo
US$88.69
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Calliditas Therapeutics Ab 0A5R London Acción Ordinaria
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.0% -
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
18/11/202100:21PRNUSCalliditas Therapeutics: Interim Report Q3, 2021
18/11/202100:12PRNUSCalliditas Therapeutics: Interim Report Q3, 2021
03/11/202103:42PRNUSCalliditas announces poster presentations at ASN Digital..
03/11/202103:40PRNUSCalliditas announces poster presentations at ASN Digital..
02/11/202104:17PRNUSCalliditas Therapeutics' nomination committee for the AGM..
07/10/202101:22PRNUSCalliditas announces acquisition of remaining Genkyotex..
07/10/202101:21PRNUSCalliditas announces acquisition of remaining Genkyotex..
16/9/202107:55PRNUSUpdated regulatory timeline for review of MAA in Europe
16/9/202107:52PRNUSUpdated regulatory timeline for review of MAA in Europe
14/9/202116:27PRNUSPDUFA goal date extension for Nefecon NDA in the U.S.
14/9/202116:26PRNUSPDUFA goal date extension for Nefecon NDA in the U.S.
31/8/202101:42PRNUSNumber of shares and votes in Calliditas Therapeutics
31/8/202101:40PRNUSNumber of shares and votes in Calliditas Therapeutics
19/8/202100:21PRNUSCalliditas Therapeutics: Interim Report Q2, 2021
19/8/202100:19PRNUSCalliditas Therapeutics: Interim Report Q2, 2021
12/8/202111:52PRNUSCalliditas Therapeutics intends to carry out a directed..
09/8/202102:15PRNUSCalliditas Receives FDA Fast Track Designation for setanaxib..
09/8/202102:14PRNUSCalliditas Receives FDA Fast Track Designation for setanaxib..
21/7/202102:05PRNUSCalliditas Therapeutics and STADA partner to register and..
15/7/202102:02PRNUSCalliditas secures $75 million term loan facility
15/7/202102:01PRNUSCalliditas secures $75 million term loan facility
28/5/202108:09PRNUSCalliditas Announces Submission of Marketing Authorisation..
28/5/202108:06PRNUSCalliditas Announces Submission of Marketing Authorisation..
28/5/202105:14PRNUSCalliditas Therapeutics to Present at Jefferies Virtual..
28/5/202105:13PRNUSCalliditas Therapeutics to Present at Jefferies Virtual..
27/5/202111:48PRNUSBulletin from the annual general meeting of Calliditas..
27/5/202111:45PRNUSBulletin from the annual general meeting of Calliditas..
18/5/202100:16PRNUSInterim Report Q1, 2021
18/5/202100:11PRNUSInterim Report Q1, 2021
14/5/202107:14PRNUSCalliditas Therapeutics to host conference call to provide..
14/5/202107:12PRNUSCalliditas Therapeutics to host conference call to provide..
03/5/202107:53PRNUSCalliditas promotes Andrew Udell to President, North America
03/5/202107:51PRNUSCalliditas promotes Andrew Udell to President, North America
28/4/202103:06PRNUSFDA grants priority review for Nefecon, for patients with..
28/4/202103:05PRNUSFDA grants priority review for Nefecon, for patients with..
27/4/202107:44PRNUSCalliditas Therapeutics AB: Change in financial calendar
27/4/202107:43PRNUSCalliditas Therapeutics' 2020 Annual Report Published
27/4/202107:42PRNUSCalliditas Therapeutics' 2020 Annual Report Published
26/4/202105:32PRNUSNotice of annual general meeting of Calliditas Therapeutics..
26/4/202105:29PRNUSNotice of annual general meeting of Calliditas Therapeutics..
23/4/202101:57PRNUSEMA Grants Accelerated Assessment Procedure for Nefecon for..
23/4/202101:55PRNUSEMA Grants Accelerated Assessment Procedure for Nefecon for..
15/3/202102:04PRNUSCalliditas Announces Submission of New Drug Application to..
15/3/202101:58PRNUSCalliditas Announces Submission of New Drug Application to..
08/3/202101:57PRNUSKamux Corporation: Flagging notification in accordance with..
08/3/202101:54PRNUSCalliditas strengthens its US Commercial and Medical Affairs..
04/3/202108:14PRNUSCalliditas Therapeutics to Host Key Opinion Leader..
04/3/202108:12PRNUSCalliditas Therapeutics to Host Key Opinion Leader..
18/2/202100:12PRNUSCalliditas Therapeutics: Year-End Report, 2020
18/2/202100:10PRNUSCalliditas Therapeutics: Year-End Report, 2020
Ver más noticias sobre esta acción »
Su Consulta Reciente
LSE
0A5R
Calliditas..
Regístrese ahora para ver estas acciones en su Monitor streaming ADVFN.

Usted puede agregar y ver hasta 110 símbolos de sus acciones favoritas al mismo tiempo y completamente gratis.

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

P: V: D:20211203 06:19:37